Your browser doesn't support javascript.
loading
New therapies for clear cell ovarian carcinoma.
Stewart, James; Cunningham, Niamh; Banerjee, Susana.
Affiliation
  • Stewart J; Royal Marsden Hospital NHS Trust, London, UK.
  • Cunningham N; Gene Function Laboratory, Insitute of Cancer Research, London, UK.
  • Banerjee S; Royal Marsden Hospital NHS Trust, London, UK.
Int J Gynecol Cancer ; 33(3): 385-393, 2023 03 06.
Article in En | MEDLINE | ID: mdl-36878571
Ovarian clear cell carcinoma is a rare subtype of epithelial ovarian cancer with unique clinicopathological features. The most common genetic aberration observed is loss of function ARID1A mutations. Advanced and recurrent ovarian clear cell carcinoma is characterized by resistance to standard-of-care cytotoxic chemotherapy and a poor prognosis. Despite the distinct molecular features of ovarian clear cell carcinoma, current treatments for this subtype of epithelial ovarian cancer are based on clinical trials which predominantly recruited patients with high grade serous ovarian carcinoma. These factors have encouraged researchers to develop novel treatment strategies specifically for ovarian clear cell carcinoma which are currently being tested in the context of clinical trials. These new treatment strategies currently focus on three key areas: immune checkpoint blockade, targeting angiogenesis, and exploiting ARID1A synthetic lethal interactions. Rational combinations of these strategies are being assessed in clinical trials. Despite the progress made in identifying new treatments for ovarian clear cell carcinoma, predictive biomarkers to better define those patients likely to respond to new treatments remain to be elucidated. Additional future challenges which may be addressed through international collaboration include the need for randomized trials in a rare disease and establishing the relative sequencing of these novel treatments.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Adenocarcinoma, Clear Cell Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans Language: En Journal: Int J Gynecol Cancer Journal subject: GINECOLOGIA / NEOPLASIAS Year: 2023 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Adenocarcinoma, Clear Cell Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans Language: En Journal: Int J Gynecol Cancer Journal subject: GINECOLOGIA / NEOPLASIAS Year: 2023 Document type: Article Country of publication: